about
Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma modelTubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenograftsAcute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressureAn overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503The biology of the combretastatins as tumour vascular targeting agents.The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell deathCharacterizing the tumor response to treatment with combretastatin A4 phosphate.Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.Vascular disrupting agents in clinical developmentVascular targeted therapies in oncology.Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agentIn-Vitro and Ex-Vivo Investigations of the Microtubule Binding Drug Targetin on Angiogenesis.Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.Halichondrin B amide acts as tubulin binding agent to exhibit anti-tumor efficacy in hematologic cancersVascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.Bypass of tumor drug resistance by antivascular therapy.Monitoring the treatment efficacy of the vascular disrupting agent CA4P.Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
P2860
Q28346776-A968415A-EAB4-4571-AC8F-EF48EF28AA39Q28482576-01C95F5B-BB00-4CBC-928E-3FA688B97C80Q30835449-D36D86F9-6B4D-4FB1-843C-2A0D0CE39697Q33217481-3FA497CC-6CF1-4175-A730-603869A5E00DQ33278296-58941BB0-E2E4-4455-B1B9-83834CD35558Q34093032-90A75DE1-96B9-410A-9853-52AFE4EE4F23Q34122191-27C68F50-AFBC-4F04-B7DA-F186A79A9895Q34296779-499B7ABD-C593-43C6-A946-318D753B5417Q34680614-ACA0469F-0672-42BF-87ED-F861F0ACB3E8Q35056257-4DFE597F-9AD7-4E88-AB28-B99D080F4332Q35793182-AD0172D4-5A36-44CD-A1B2-9346B3326D62Q36648929-4294A727-B020-4412-AD95-49A0BE1B35E6Q36756648-829C7165-A192-4B26-A09F-AE9B5753B9DAQ36765436-75249290-5732-4371-BD10-C2B5E04DE3FFQ37254370-F64CF267-38E1-45A6-A68C-71330F7DBC69Q37340510-2157684D-CD54-4DAB-8554-AEA2F39DCDAFQ37709945-A8DC4F6F-3A5C-4B37-8E93-178DE167A1C2Q38168371-A8B5F2CD-75C6-4C34-93AE-C431F52806AEQ38803373-DCF77CDD-85F5-4BB1-9CDD-CF456425E22CQ41552582-AE0B8BAF-87AE-4235-8782-8739310B54ADQ41602514-E27ABFAE-E698-4768-AF42-464C337EE681Q42400154-28707E0C-FB5A-4919-901B-3D3B3D763D10Q49441016-2EEB5421-B3C7-4D91-9874-A64CEEE0A580
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Tumour vasculature as a target for cancer therapy.
@ast
Tumour vasculature as a target for cancer therapy.
@en
type
label
Tumour vasculature as a target for cancer therapy.
@ast
Tumour vasculature as a target for cancer therapy.
@en
prefLabel
Tumour vasculature as a target for cancer therapy.
@ast
Tumour vasculature as a target for cancer therapy.
@en
P1476
Tumour vasculature as a target for cancer therapy
@en
P2093
Chaplin DJ
Dougherty GJ
P407
P478
80 Suppl 1
P577
1999-07-01T00:00:00Z